Clinical Trials for the Treatment of Sepsis

Clinical Trials for the Treatment of Sepsis

106,99 €*

lieferbar in ca. 2-4 Werktagen

Falls Sie eine Lieferung außerhalb DE, AT oder CH wünschen, nutzen Sie bitte unser Kontaktformular für eine Anfrage.

Sepsis and Innovative Treatment: The Odyssey R. C. Bone The Odyssey by Homer, dates back to the 8th century, B. C. [1]. It is a great epic adventure of Odysseus's dramatic journey from Troy back home to Ithaca. Odysseus survives the ordeals of this journey and returns with new powers and insights. The study of the pathogenesis and treatment of sepsis has also been an odys sey. I feel we will return from this odyssey with new insights and treatments. However, as with Odysseus, this will occur only after considerable struggle. In the 1980s we had a rather simplistic view of sepsis. It was a highly lethal complication caused by infection and often charac terized by shock and multi-organ failure. Our knowledge of the inflammatory responses associated with sepsis was embryonic compared to today. The inflammatory response was often treat ment with mega-dose corticosteroids along with fluid resuscita tion, vasopressors and antibiotics. Because of the paucity of mul ti-center controlled trials documenting the risk/benefit ratio of the treatment of sepsis with corticosteroids, two large multi-cen ter controlled trials were organized to evaluate the role of corti costeroids in sepsis [2, 3]. Because animal models showed bene fits of corticosteroids only with pre-treatment or early treatment, a definition of sepsis was used that did not require positive cul ture documentation or septic shock to be included in the studied population.

Epidemiology of Sepsis
The Systemic Inflammatory Response Syndrome (SIRS)
The "At Risk" Patient Population
Outcome and Prognostic Factors in Bacteremic Sepsis
ARDS and Sepsis: Resemblances and Differences
Monitoring the Treatment of Sepsis
Microbiological Requirements for Studies of Sepsis
Measurement of Inflammatory Mediators in Clinical Sepsis
Whole Body and Organ Measures of 02 Availability
Multiple Organ Dysfunction Syndrome (MODS)
Monitoring Illness Severity
What Determines Prognosis in Sepsis?
SAPS II and MPM II Models for Early Severe Sepsis
Clinical Management of Sepsis
Fluid Therapy in Septic Shock
Role of RBC Transfusion Therapy in Sepsis
Vasoactive Drug Therapy in Sepsis
Evidence-Based Analysis of Nutrition Support in Sepsis
Investigational Therapy of Sepsis
Anti-Endotoxin Therapy
Critical Reappraisal of Steroids and Other Anti-Inflammatory Agents
Investigational Therapy of Sepsis: Anti-TNF, IL-1ra, Anti-PAF and G-CSF
Sepsis and Acute Lung Injury
Increasing Oxygen Delivery in Sepsis
Designing the Optimum Clinical Trial for the Treatment of Sepsis
Critical Evaluation of the Design and Conduct of Previous Clinical Trials in Sepsis
Evaluation of the Adequacy of Source Control
Statistical Considerations for the Design of the Optimal Clinical Trial
The Monitoring and Reporting of Clinical Trials
Economic Evaluation in the Critical Care Literature
Ethical Issues in Clinical Trials.
ISBN 978-3-642-79226-7
Artikelnummer 9783642792267
Medientyp Buch
Auflage Softcover reprint of the original 1st ed. 1995
Copyrightjahr 2012
Verlag Springer, Berlin
Umfang XXXI, 406 Seiten
Abbildungen XXXI, 406 p.
Sprache Englisch